Is RNASEL:p.Glu265* a modifier of early-onset breast cancer risk for carriers of high-risk mutations?-Reference-Cited by-同舟云学术

Is RNASEL:p.Glu265* a modifier of early-onset breast cancer risk for carriers of high-risk mutations?

Published:2018-02-08 Issue:1 Volume:18 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Nguyen-Dumont Tú, ,Teo Zhi L.,Hammet Fleur,Roberge Alexis,Mahmoodi Maryam,Tsimiklis Helen,Park Daniel J.,Pope Bernard J.,Lonie Andrew,Kapuscinski Miroslav K.,Mahmood Khalid,Goldgar David E.,Giles Graham G.,Winship Ingrid,Hopper John L.,Southey Melissa C.^ORCID

Funder

National Cancer Institute

National Health and Medical Research Council

Victorian Life Sciences Computation Initiative

University of Melbourne

Région Rhône-Alpes, France

VBCRC

National Breast Cancer Foundation

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-018-4028-z.pdf

Reference20 articles.

1. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast cancer linkage consortium. Am J Hum Genet. 1995;56(1):265–71.

2. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium Am J Hum Genet. 1998;62(3):676–89.

3. Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE, CIMBA. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the consortium of investigators of modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res. 2007;9(2):104.

4. John EM, Hopper JL, Beck JC, Knight JA, Neuhausen SL, Senie RT, Ziogas A, Andrulis IL, Anton-Culver H, Boyd N, et al. The breast cancer family registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res. 2004;6(4):R375–89.

5. Southey MC, Teo ZL, Dowty JG, Odefrey FA, Park DJ, Tischkowitz M, Sabbaghian N, Apicella C, Byrnes GB, Winship I, et al. A PALB2 mutation associated with high risk of breast cancer. Breast Cancer Res. 2010;12(6):R109.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The performance of multi-gene panels for breast/ovarian cancer predisposition;Clinica Chimica Acta;2023-01

2. Multi-gene panel testing increases germline predisposing mutations’ detection in a cohort of breast/ovarian cancer patients from Southern Italy;Frontiers in Medicine;2022-08-11

3. Activation of the viral sensor oligoadenylate synthetase 2 (Oas2) prevents pregnancy-driven mammary cancer metastases;Breast Cancer Research;2022-05-03

4. A phenolic small molecule inhibitor of RNase L prevents cell death from ADAR1 deficiency;Proceedings of the National Academy of Sciences;2020-09-21

5. A Systematic Literature Review of Whole Exome and Genome Sequencing Population Studies of Genetic Susceptibility to Cancer;Cancer Epidemiology Biomarkers & Prevention;2020-05-28